Zacks: Warner Chilcott can withstand generic threats
NEW YORK — Drug maker Warner Chilcott’s diversified portfolio of drugs will help it weather generic challenges to its patents, according to a new report by Zacks Investment Research.
Zacks noted that Warner Chilcott recently had received a notice from Zydus Pharmaceuticals USA that the latter would seek to challenge a patent covering the ulcerative colitis drug Asacol HD in order to market a generic version by filing a regulatory approval application with the Food and Drug Administration containing a paragraph IV certification, a legal assertion that the patent is invalid, unenforceable or won’t be infringed.
The patent in question is set to expire in November 2021, though Warner Chilcott plans to sue to protect it. Zacks said other drugs made by Warner Chilcott face generic competition as well, though the firm didn’t specify which ones and took a "neutral" stance on the company.
Lilly announces senior management changes
INDIANAPOLIS — Two senior leaders at Eli Lilly are retiring, the company said Tuesday.
The Indianapolis-based drug maker announced the Dec. 31 retirements of Lilly SVP and Bio-Medicines president Bryce Carmine, and president of manufacturing operations Frank Deane. Carmine and Deane have worked at Lilly for 36 years and 33 years, respectively. Lilly USA president Dave Ricks will replace Carmine, while SVP global drug product manufacturing Maria Crowe will replace Deane.
"We’ll certainly miss Bryce and Frank and the extraordinary leadership they provided," Lilly chairman, president and CEO John Lechleiter said. "At the same time, we’re very fortunate to have talented leaders who are well prepared and ready to step into these critical roles."
Bazi International introduces superfruit energy shot
DENVER — Bazi International on Tuesday launched its energy shot Bazi, which contains a blend of eight superfruits.
According to the company, only 3-out-of-10 consumers have tried energy shots or drinks. Some of the key barriers of entry include health and safety concerns and an underlying belief that the shots are not good for you.
"Being successful in the increasingly crowded beverage and shot categories, products must be differentiated to be successful," stated Bazi CEO Debbie Wildrick. "Bazi is unique in that it provides the body with an enhanced blend of energy and nutrition, [and] is supercharged with antioxidants and powerful nutrients."